GNLX Genelux Corp: ערך חשבונאי למניה

Genelux Corporation (GNLX) develops anti-tumor systems through partnerships with scientific centers, utilizing automated virus incubation modules to eliminate human error. This daily price action reflects the activity of the asset, which has a metric of 0.36. The business focuses on the development of oncolytic agents for solid tumors, awaiting key Phase III trial data and synergy with immunotherapy.

A conservative investor evaluates this metric as the ratio of equity to the number of shares, which allows for the determination of the real value of net assets through a historical assessment of the book value per share. For Genelux Corporation (GNLX), the growth of this indicator confirms capitalization driven by advances from pharma behemoths for the development of Olvi-Vec, creating a solid financial foundation prior to reaching break-even.